Stallmach et al. retrospectively collected data on the rescue use of anti-TNF in patients suffering severe COVID-19 and they found a reduced mortality [35] with only one of seven infliximab- (IFX-) treated patients dying as compared to one-third of 17 patients without IFX. This evidence concerns the gene TNF and COVID-19.